Medimmune Limited

Dorin Toader

Lakshmaiah Gingipalli

Fengjiang Wang

Changshou Gao

Nazzareno Dimasi

Melissa Marie Damschroder

John H Li

Andy Q Yuan

Godfrey Rainey

Cuihua Gao

Srinath Kasturirangan

Ryan Fleming

Steven Roy Coats

Binyam Bezabeh

Pamela Thompson

Andy Qingan Yuan

The present disclosure relates to a process for preparing antibodies with a defined glycosylation pattern, in particular antibodies with a glycan terminating in an N-acetylglucosamine. The antibodies of the disclosure are suitable for use in a process to conjugate a payload thereto. The disclosure also extends to molecules obtained and obtainable from the process disclosed herein, novel molecules and intermediates, compositions comprising said molecules and uses of the molecules and compositions, particularly in treatment, for example in the treatment of cancer.

Methods for preparing antibodies with a defined glycosylation pattern

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Bispecific HER2 antibodies

Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.

Tubulysin derivatives

Growing community of inventors

Gaithersburg, MD, United States of America

Dorin Toader